polyethylene glycol Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
PEG or peg may refer to:   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Over the Counter
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.0159 - $1.7013
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( potassium chloride (klor-con), sodium sulfate, sodium bicarbonate, sodium chloride, polyethylene glycol - other names: clenz-lyte, co-lav, colovage, colyte, colyte-flavore, colyte with flavor packs, glycoprep, go-evac, ocl, peg 3350 and electrolytes, polyethylene glycol 3350 and electrolytes )
|
( bisacodyl (Halflytely), potassium chloride (klor-con), sodium bicarbonate, sodium chloride, polyethylene glycol - other name: peg-3350, sodium chloride, sodium bicarbonate, potassium chloride and bisacodyl )
|
( vitamin c, potassium chloride (klor-con), sodium sulfate, sodium chloride, polyethylene glycol - other names: peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic aci, plenvu )
|
( potassium chloride (klor-con), sodium bicarbonate, sodium chloride, polyethylene glycol - other names: lax-lyte with flavor packs, nulytely, peg-3350, potassium chloride, sodium bicarbonate, sodium chloride, trilyte )
|
( potassium chloride (klor-con), magnesium sulfate (Tis-U-Sol), potassium sulfate, sodium sulfate, sodium bicarbonate, sodium chloride, polyethylene glycol )
|
( potassium chloride (klor-con), magnesium sulfate (Tis-U-Sol), sodium sulfate, sodium chloride, polyethylene glycol )

Alternative names

ajg555 | asp3350 | bli4700 | colyte | dcl-101 | e1521 | glycolax | golytely | isocolan | lutrol e | macrogol 3350 | macrogol 4000 | macrogol 6000 | macrogolol | miralax | nulytely | peg | peg3350 | peg 3350 | peg-3350 | peg 400 | peg-400 | peo-400 | pluracol e | poe | polyethelene glycol | polyethylene glycol | polyethylene glycol 300 | polyethylene glycol 3350 | polyethylene glycol 400 | polyethylene glycol 4000 | polyethylene glycol 6000 | polyethylene oxide | polyglycol e 300, e 400, e 1450, e 8000 | polyoxyethylene | sf-els | suclear | systane

Organizations (366)

Research & Development (339)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (30)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (96)

Approved Indications (2)


 

Colonoscopy (approved 1984)

Constipation

Experimental Indications - Clinical Trial Phases 1-4 (96)


 

Acute-On-Chronic Liver Failure (Phase 4)

Adenoma (Phase 4)

Anastomotic Leak (Phase 3)

Autism Spectrum Disorder (Phase 2)

Blepharitis (Phase 3)

Capsule Endoscopy (Phase 4)

Cataract (Phase 4)

Cathartics (Phase 4)

Celiac Disease (Phase 4)

Clostridioides difficile (Phase 2/Phase 3)

Clostridium Infections (Phase 4)

Colitis, Ulcerative (Phase 4)

Colon (Phase 4)

Colonic Diseases (Phase 4)

Colonic Neoplasms (Phase 4)

Colonic Polyps (Phase 4)

Colonoscopy (Phase 4)

Colorectal Neoplasms (Phase 4)

Colorectal Surgery (Phase 4)

Constipation (Phase 4)

Critical Illness (Phase 3)

Crohn Disease (Phase 2)

Cystic Fibrosis (Phase 4)

Dermatology (Phase 2)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Diabetic Retinopathy (Phase 2)

Diagnosis (Phase 4)

Dialysis (Phase 4)

Diarrhea (Phase 2)

Digestive System Diseases (Phase 3)

Diurnal Enuresis (Phase 4)

Diverticulitis (Early Phase 1)

Diverticulum (Phase 4)

Drug Resistance, Bacterial (Phase 1/Phase 2)

Drugs, Investigational (Phase 4)

Dry Eye Syndromes (Phase 4)

Dysbiosis (Phase 4)

Dyskinesias (Phase 3)

Endoscopy (Phase 4)

Exanthema (Phase 2)

Facial Paralysis (Phase 2)

Fear (Phase 2/Phase 3)

Fecal Impaction (Phase 2)

Feces (Phase 4)

Fissure in Ano (Phase 4)

Gastric Emptying (Phase 1)

Gastrointestinal Diseases (Phase 4)

Gastrointestinal Hemorrhage (Phase 4)

Gender Dysphoria (Phase 2/Phase 3)

General Surgery (Phase 4)

Glycemic Control (Phase 2)

Hamartoma (Phase 4)

Hand Injuries (Phase 1)

Healthy Volunteers (Phase 4)

Hepacivirus (Phase 2)

Hepatic Encephalopathy (Phase 4)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

HIV (Phase 1/Phase 2)

Hospitalization (Phase 4)

Hyperkalemia (Phase 4)

Infections (Phase 2/Phase 3)

Inflammatory Bowel Diseases (Phase 4)

Intestinal Diseases (Phase 4)

Intestinal Neoplasms (Phase 4)

Intestine, Large (Phase 4)

Kidney Neoplasms (Phase 4)

Klebsiella pneumoniae (Phase 1/Phase 2)

Macular Edema (Phase 2)

Magnesium Sulfate (Phase 2)

Melanoma (Phase 2)

Motor Activity (Phase 3)

Myopia (Phase 4)

Neoplasm Metastasis (Early Phase 1)

Neoplasms (Phase 4)

Nerve Fibers (Phase 1/Phase 2)

Nocturnal Enuresis (Phase 4)

Ophthalmology (Phase 4)

Parkinson Disease (Phase 3)

Peripheral Nerve Injuries (Phase 2)

Polyethylene Glycols (Phase 4)

Postoperative Complications (Phase 4)

Pregnancy Complications (Phase 2/Phase 3)

Prolapse (Phase 4)

Prostatic Neoplasms (Phase 4)

Radiodermatitis (Phase 2)

Renal Insufficiency, Chronic (Phase 4)

Retinal Diseases (Phase 2/Phase 3)

Sarcoma (Early Phase 1)

Staphylococcal Infections (Phase 4)

Surgical Wound Infection (Early Phase 1)

Venous Cutdown (Phase 3)

Vision Disorders (Phase 4)

Vitreoretinopathy, Proliferative (Phase 2/Phase 3)

Xerophthalmia (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 385
  • # of Trial Organizations: 339

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue